<< Report on the U.S. Pharmaceutical Preparation Manufacturing Industry | Stem cells - the answer to autoimmune diseases and cancer in the future >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Ελληνικά | Русский | Svenska | Polski

SSO2 administration reduces heart muscle damage

Published on September 16, 2009 at 5:00 AM · No Comments

American Heart Association rapid access journal report

Supersaturated oxygen (SSO2) administered during catheter-based treatments for heart attack can significantly reduce heart muscle damage, according to a new study reported in Circulation: Cardiovascular Interventions, a journal of the American Heart Association.

In another study from the same issue, a different group of researchers found that manually removing a blood clot provided greater recovery of heart function after a heart attack.

"The greatest benefits were seen in the patients most at risk," said Gregg W. Stone, M.D., lead author of the SSO2 study, and professor of medicine at Columbia University Medical Center in New York, N.Y. "The larger the heart attack, the more heart muscle salvaged."

SSO2 - highly concentrated oxygen mixed in blood and delivered to the area of heart muscle dying after a heart attack - showed promise in animal studies and a previous human trial (AMIHOT-I). So Stone and his colleagues conducted AMIHOT-II with a similar protocol, focusing on patients with anterior ST-segment elevation myocardial infarctions (STEMIs) who were treated within six hours of heart attack symptoms.

"STEMIs are the large attacks," Stone said. "They have a really bad early prognosis because there is so much heart muscle lost." When a large area of the heart is damaged, heart failure is more likely.

Of the 733,000 Americans who suffer acute coronary syndromes (i.e. heart attack or chest pain) each year, 361,000 (almost half) have a STEMI. Catheter-based percutaneous coronary intervention (PCI) is a procedure that can effectively open blocked arteries in STEMI patients.

The AMIHOT-II researchers studied 301 STEMI patients who arrived within six hours after the onset of symptoms at 20 sites in four countries. The researchers randomized 222 to receive PCI plus SSO2 - infused for 90 minutes during treatment -- and 79 to PCI only. Some of their analyses also included data pooled from 101 patients from the AMIHOT-I.

Major study findings included:

  • In AMIHOT-II patients, heart damage 14 days after treatment averaged 26.5 percent of the left ventricle for PCI-only patients and 20 percent for the PCI plus SS02 group. Pooled data from both AMIHOT studies showed 25 percent damage in PCI-only patients and 18.5 percent in the SSO2 group.

  • Among 154 patients whose left ventricle ejected less than 40 percent of the blood with each contraction prior to treatment, the PCI-only group had 33.5 percent damage versus 23.5 percent in the SSO2 patients. "For patients with large heart attacks, this is the first therapy shown to be beneficial in an adequately powered, multicenter trial," Stone said.

  • In those with more than 40 percent blood ejection, muscle damage was 16.5 percent in PCI-only patients and 12.5 percent in the SSO2 group, which is a similar relative reduction in heart attack size as in patients with larger attacks, but a smaller absolute reduction.

  • Researchers found no significant differences between the two groups of AMIHOT-II patients in the levels of blood markers that indicate a heart attack, or in the percentage of heart muscle at risk of dying, which was measured three hours after treatment.

  • At 30 days post-op, the pooled data showed the two groups had similar percentages of major adverse events - death, another heart attack, reopening the same heart artery and stroke: 4.7 percent for the SSO2 patients and 5.1 percent for PCI-only group.
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading